June 17th 2021
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
November 18th 2014
June 13th 2013
June 12th 2013
Task Force issues vitamin D and calcium supplement recommendations
February 25th 2013The US Preventive Services Task Force (Task Force) issued its final recommendation on vitamin D and calcium supplements for the prevention of fractures, of which there are several individual recommendations for people who do not live in assisted living or nursing homes.
Breast cancer vaccine possibility to be studied through grant
February 14th 2013The National Breast Cancer Coalition recently awarded a nearly $200,000 seed grant to two researchers who will study the viral connection to breast cancer. The research will assess the infectious agent in breast tumors compared to normal breast tissue, which could lead to a preventive vaccine.
Blood pressure agents, NSAID combo linked to kidney risks
January 31st 2013Patients who take a combination of diuretics and either angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and add NSAIDs, have an increased risk of acute kidney injury, according to a study online in BMJ.
FDA Actions in Brief January 2013
January 31st 2013Recent FDA Approvals (through January 2013) related to (Deferasirox, Exjade, Novartis, bevacizumab, Avastin, Roche Group, trivalent influenza vaccine, Flublok, Protein Sciences, Budesonide, Uceris, Santarus, pooled plasma blood product, Octaplas, Octapharma, Sumatriptan iontophoretic transdermal system, Zecuity, NuPathe, onabotulinumtoxinA, Botox, Allergan
Type 2 diabetes: A focus on new guidelines
January 31st 2013Diabetes mellitus is a chronic condition characterized by elevated blood glucose that occurs as a result of impaired insulin action or production. This article focuses on current recommendations for the treatment of type 2 diabetes and methods of controlling co-occurring conditions.
FDA: Guidance on development of abuse-deterrent opioid formulations
January 31st 2013FDA issued a draft guidance last month to help the industry in the development of opioid drug formulations with abuse-deterrent properties, saying it considers development of these products a high public health priority.
FDA approves deferasirox to remove excess iron in patients with genetic blood disorder
January 23rd 2013FDA has expanded the approved use of deferasirox (Exjade, Novartis) to treat patients aged 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
Study raises concern over cefixime failure rate for gonorrhea
January 21st 2013Researchers examining the effectiveness of cefixime in the treatment of gonorrhea found a relatively high treatment failure rate, raising concern that gonorrhea may become untreatable, according to results published January 9 in the Journal of the American Medical Association.